PET/CT scan testing for spread in metastatic prostate cancer
Treatments studied
Part of Cancer clinical trials.
This study tests how well an FTT PET/CT scan can detect and measure metastatic (spread) prostate cancer. It may help your care team decide on the best next treatment plan, especially if you need to change or start therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have a confirmed diagnosis of prostate cancer from tissue testing (biopsy or surgery)
- Your cancer has evidence of spreading, seen on standard scans like CT, MRI, bone scan, or PET/CT
- You are being considered for a new or changed treatment that may include a PARP inhibitor, hormone therapy (ADT), and/or chemotherapy
- You can and will sign a consent form and follow study procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a special type of PET/CT scan (using a tracer called 18F-PSMA) with a regular CT scan to see which is better at checking for prostate cancer spread. It may help improve how your cancer is monitored.
This study uses a special type of PET/CT scan (FAPI) to see if it can better detect where prostate cancer has spread in men with newly diagnosed, high-risk disease. It may help doctors plan more accurate treatment.
This study is testing a special type of PET/CT scan using a tracer called FTT to see if it can better find and track pancreatic neuroendocrine tumors that have spread or cannot be removed by surgery. The goal is to improve imaging for people with this type of cancer.
This early study uses a special PET/CT scan to see how much a specific cancer-related protein (PARP-1) is present in pheochromocytoma and paraganglioma. It may help doctors understand the biology of these tumors and how useful this scan could be in the future.
This trial uses special PET imaging to see where progressive prostate cancer is in the body—one tracer to look at general sugar use and one designed to detect testosterone-related activity. It may help doctors better map cancer spread so future treatment planning can be more targeted.
This study follows people with prostate cancer whose PSA blood test has risen again after standard treatment. It uses an approved PET scan tracer to look for cancer spread, which may help doctors understand how the disease is progressing.
Hear when a new Prostate Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.